Kyowa Hakko Kirin, Otsuka Pharmaceutical sales and marketing update

Kyowa said once-daily oral Onglyza saxagliptin has been listed on the Japanese National Health Insurance (NHI) with a list price of ¥110.20 ($1.10) per 2.5 mg tablet and ¥166 ($1.65) per 5 mg tablet. The company said it is preparing to launch the product, which was approved in Japan in March to treat Type II diabetes. Kyowa has exclusive, Japanese rights to develop and commercialize saxagliptin under a June 2012 deal (see BioCentury, July 2, 2012 & April 1, 2013). ...